Navigation Links
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Date:1/6/2009

Program Expands on Successful Results from prior U.S., U.K. and China Trials

SAN DIEGO, Jan. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, today announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.

This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.

ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.

For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.

VTI Chairman and CE
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
2. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
3. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys,Genetics ... portfolio of,therapeutic proteins for metabolic and cardiovascular ... a scientific poster and,abstract at the 67th ... in Chicago. The Company's poster will disclose,recent ...
... Follow,Presentation, DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- ... of its,leading product candidate, VIAject(TM), at the 67th ... held in,Chicago, June 22 through June 26. , ... place on June 22,from 4:15 - 6:15pm CST, ...
Cached Medicine Technology:SemBioSys to present new data at American Diabetes Association,annual meeting 2SemBioSys to present new data at American Diabetes Association,annual meeting 3Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3
(Date:8/28/2015)... , ... August 29, 2015 , ... Rio Salado ... learning and the student experience as part of the EDUCAUSE - Next Generation Learning ... . , This is the third Breakthrough Models Incubator hosted by EDUCAUSE ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... With the ... concert returned for the second year to the Adams County Fairgrounds in Mendon, IL ... held to raise money to support music education in the underfunded school districts of ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Reporter , MONDAY, Nov. 22 (HealthDay News) -- Diabetes ... a new study shows. The research, conducted at ... had a much higher risk of developing diabetes, and ... depression, compared to healthy study participants. "This study ...
... Minn. -- A new Mayo Clinic study ... low-grade brain tumors (gliomas) ( http://www.mayoclinic.org/brain-tumors/ ) ... the tumor have an increased chance of ... possible, adding radiation therapy to a less ...
... helping researchers learn whether more muscle improves the cardiovascular ... ways to counteract the unhealthy effects of fat," said ... of Georgia Vascular Biology Center and co-director of MCG,s ... the risk for cardiovascular disease as well as diabetes, ...
... Reinberg HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... taken off the market, emergency rooms treat less than half ... reactions to the drugs, a new U.S. government study shows. ... for children aged 2 and under took effect in October ...
... Biochemist and protein crystallographer Dr. Oliver Daumke of the ... has won the "Bayer Early Excellence in Science Award ... prize worth EUR 10,000 for his contributions to the ... proteins next spring in Berlin. Together with him, two ...
... , MONDAY, Nov. 22 (HealthDay News) -- Infants with Down syndrome ... risk for heart and lung disorders that increase their chances of ... medical records of more than 50,000 very low birth weight (VLBW) ... They found that among this group of babies, those born with ...
Cached Medicine News:Health News:Diabetes, Depression Can Be Two-Way Street 2Health News:Diabetes, Depression Can Be Two-Way Street 3Health News:Mayo Clinic study finds aggressive surgery is best for children with brain tumors 2Health News:Fat yet muscular mouse provides clues to improving cardiovascular health 2Health News:Kids' ER Visits Down After Cold Medicine Withdrawal 2Health News:Kids' ER Visits Down After Cold Medicine Withdrawal 3Health News:Tiniest Newborns With Down Syndrome Face Other Health Risks 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: